Form 4: SI-BONE CFO Reports RSU Grants and Tax-Related Stock Sales

SI-BONE's Chief Financial Officer, Anshul Maheshwari, reported the acquisition of restricted stock units and subsequent non-discretionary sales to cover tax obligations.

Summary

• Anshul Maheshwari, Chief Financial Officer of SI-BONE, Inc. (SIBN), reported transactions involving the company's common stock.
• On February 16, 2026, Maheshwari was granted 80,994 restricted stock units (RSUs) which will vest over four years in quarterly installments, beginning February 15, 2026.
• Additionally, on February 16, 2026, Maheshwari received two grants of 13,499 restricted stock units each, totaling 26,998 RSUs, which will vest over three years based on the Issuer's total shareholder return (TSR) performance against a peer group.
• On February 17, 2026, Maheshwari sold a total of 21,528 shares of common stock in multiple transactions at weighted average prices ranging from $15.2881 to $15.4597 per share.
• These sales were non-discretionary 'sell to cover' transactions, executed solely to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Maheshwari beneficially owns 266,466 shares of common stock, which includes 200,237 shares issuable upon the settlement of restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While there are sales, they are non-discretionary for tax purposes, and the significant RSU grants, including performance-based ones, indicate continued executive alignment and incentive for future company growth.

Positives

• The reporting person, a key executive, received significant grants of restricted stock units (totaling 107,992 shares), aligning management's interests with long-term shareholder value.
• A portion of the RSU grants (26,998 shares) are performance-based, tied to the company's Total Shareholder Return (TSR) relative to peers, incentivizing strong performance.

Negatives

• The Chief Financial Officer sold 21,528 shares of common stock, reducing direct beneficial ownership, although these sales were non-discretionary and for tax purposes.

Future Outlook

The filing details future vesting schedules for restricted stock units, with some vesting over four years starting February 15, 2026, and others over three years based on future Total Shareholder Return performance.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and subsequent 'sell to cover' transactions are standard practices in executive compensation across the medical device and broader technology sectors. These mechanisms are designed to align executive incentives with long-term company performance while managing tax liabilities associated with equity awards.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a significant component of executive compensation is a common practice across publicly traded companies, particularly in growth-oriented sectors like medical technology, aligning executive interests with shareholder value creation.
• The inclusion of performance-based vesting conditions, such as Total Shareholder Return (TSR) relative to a peer group, is an increasingly adopted best practice in corporate governance, seen in companies like Medtronic (MDT) and Stryker (SYK), to ensure compensation is directly tied to competitive market performance.
• The 'sell to cover' mechanism for tax withholding is a standard, non-discretionary transaction for executives receiving equity compensation, widely observed across all industries and not indicative of a discretionary sale of shares.

Stakeholder Impact

• Shareholders: The RSU grants align the CFO's long-term interests with shareholder value, particularly the performance-based awards. The 'sell to cover' sales are routine and not indicative of a change in confidence.
• Employees: Standard executive compensation practices are being followed, which can be a positive signal for overall compensation strategy.

Next Steps

• The granted restricted stock units will vest in quarterly installments over four years starting February 15, 2026, for the time-based awards.
• The performance-based restricted stock units will vest over three years based on the Issuer's total shareholder return (TSR) as measured against a set of peer companies.

Key Dates

Keywords

SI-BONE, SIBN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Sell to Cover, Executive Compensation, Chief Financial Officer, Equity Compensation